What Is the Average Age of Death for Someone With Parkinson’s?

In large cohort studies, the average age of death for someone with Parkinson’s disease falls roughly in the late 70s, typically around 78 to 80 years old. A long-running Australian study, for instance, found an average age at death of 78.0 years for people with Parkinson’s, compared with 80.4 years for matched controls without the disease.¹ That gap sounds modest, but the picture is more complicated than a single number can capture, because when someone is diagnosed, what complications develop, and how aggressively symptoms are managed all shift the trajectory in ways that matter.

How Much Does Parkinson’s Shorten a Lifespan?

Researchers usually express the mortality impact of Parkinson’s as a standardized mortality ratio, which compares death rates in people with the disease to those in the general population matched for age and sex. In the Queensland study mentioned above, that ratio was about 2.75, meaning people with Parkinson’s were roughly two and a half times more likely to die in any given year than peers without it.¹ A population-based study from Olmsted County, Minnesota, found a somewhat lower ratio of 1.84 for all patients with parkinsonism, which includes conditions that can be mistaken for Parkinson’s.²

An analysis of levodopa-treated patients in the United States put the average life-span reduction at about seven years compared with age-, sex-, and race-matched controls, with an overall observed-to-expected mortality ratio of 2.66.³ That study also uncovered a surprising sex difference: women with Parkinson’s had a greater relative reduction in lifespan than men. Men lost roughly five years on average compared with male controls, while women lost about seven years, and the mortality ratio for women was 3.76 versus 2.28 for men.³ The reasons are not fully settled, but hormonal changes after menopause, differences in disease presentation, and disparities in treatment response have all been proposed as contributing factors.

Why Age at Onset Changes Everything

One of the strongest predictors of how long someone lives with Parkinson’s is the age when symptoms first appear. A person diagnosed in their 30s will, statistically, live with the disease for decades. A study tracking survival by age at onset found that people diagnosed between ages 20 and 39 had a median survival of about 32.5 years, while those diagnosed after 80 had a median survival of roughly 7 years.⁴ That is a staggering range, and it explains why single “average age of death” numbers can be misleading. Someone diagnosed at 35 who lives another 32 years dies around 67. Someone diagnosed at 75 who lives another 10 years dies at 85. Their experiences of the disease are almost incomparable.

Young-onset Parkinson’s, though, carries its own burden. Those patients live many more years with progressive disability, and their mortality relative to their age-matched peers is actually elevated more steeply than it is for people diagnosed later. The disease takes a bigger relative toll when you have more expected years ahead of you. From a practical standpoint, a younger person diagnosed with Parkinson’s should expect a long road and should plan for decades of symptom management, career adjustments, and evolving care needs.

What People With Parkinson’s Actually Die From

Parkinson’s itself does not directly kill most people. Instead, it creates conditions that make other causes of death more likely. A nationwide population-based study found that the leading cause of death listed on death certificates for Parkinson’s patients was nervous system diseases, which accounted for about 39% of deaths, and nearly all of those were classified as movement-related disorders. Circulatory diseases came next at about 15%, followed by respiratory diseases at roughly 13%, and cancer at about 10%.⁵

Those broad categories hide what actually happens at the bedside in late-stage disease. A study focused specifically on patients in the final stages found that aspiration pneumonia was the most common proximate cause of death, responsible for about 34% of hospital deaths. Sepsis accounted for 16%, unspecified pneumonia for 13%, bowel obstruction for 5%, and COVID-19 for another 5%.⁶ Aspiration pneumonia stands out because it reflects a direct consequence of the disease: as Parkinson’s progresses, the muscles involved in swallowing lose coordination, food or liquid enters the airway, and infection follows. This is one of the most important risks for families and caregivers to understand, because swallowing difficulties can be monitored and partially managed with speech therapy, dietary changes, and careful feeding practices.

One thing worth noting: Parkinson’s does not appear to independently raise the risk of major cardiovascular events like heart attack or stroke. A retrospective cohort study found that after adjusting for other risk factors, a Parkinson’s diagnosis itself did not predict cardiovascular events. The usual suspects like diabetes, smoking, kidney disease, and atrial fibrillation drove cardiovascular risk just as they would in someone without Parkinson’s.⁷ This matters because it means managing standard heart-health risk factors is just as important for someone with Parkinson’s as for anyone else, and those efforts are not wasted on a disease that would override them anyway.

Dementia and Psychosis as Survival Markers

Cognitive decline is one of the most feared complications of Parkinson’s, and it is also one of the strongest predictors of shorter survival. A large multi-cohort study found that dementia symptoms more than doubled the risk of death in Parkinson’s patients, with a hazard ratio above 2.0 across three independent cohorts.⁸ That is a substantial effect. Someone with Parkinson’s who develops dementia faces a considerably shortened timeline compared with someone whose cognition stays relatively intact.

Parkinson’s disease psychosis, which involves hallucinations or delusions, carries its own heavy toll. A retrospective study found that people who developed psychosis had a 34% higher risk of death than those who did not, and they were more than three times as likely to move into institutional care within a year of the psychosis diagnosis.⁹ Within five years, roughly a quarter of people with Parkinson’s psychosis had entered custodial care, compared with about 10% of those without psychosis.⁹ Psychosis is often underreported because patients and families may not recognize hallucinations as part of the disease, or may feel uncomfortable bringing them up. Early identification lets clinicians adjust medications that may be contributing to psychotic symptoms and potentially slow the cascade toward institutionalization.

Genetic Variations and Their Effect on Survival

Not all Parkinson’s disease has the same genetic underpinning, and those differences show up in how long people survive. Mutations in the LRRK2 gene, one of the most commonly identified genetic causes of Parkinson’s, appear to be associated with a milder disease course. A study comparing survival across genetic groups found that LRRK2 carriers tended to live longer than people with idiopathic (no identified genetic cause) Parkinson’s, though the difference did not reach statistical significance in the full multivariate analysis.¹⁰ A separate analysis reinforced this finding, describing LRRK2-related Parkinson’s as having a milder phenotype overall.¹¹

Mutations in the GBA gene, by contrast, did not clearly affect mortality compared with idiopathic Parkinson’s in the same analysis.¹⁰ However, a separate genetic factor did matter: the APOE ε4 allele, which is better known for its role in Alzheimer’s disease risk, was independently associated with shorter survival in Parkinson’s patients even after accounting for whether they had dementia.⁸ That finding is relatively new and hints at shared biology between Parkinson’s and Alzheimer’s that goes beyond just cognitive decline. For someone who has had genetic testing and carries the APOE ε4 variant, this is an additional piece of the prognosis puzzle, though it does not change treatment decisions on its own at this point.

Deep Brain Stimulation and Long-Term Survival

Deep brain stimulation, a surgical procedure that implants electrodes in specific brain regions to regulate abnormal nerve signals, is one of the most established interventions for Parkinson’s motor symptoms. It does not cure the disease, but it can dramatically improve quality of life for years. The question of whether it also affects survival is harder to answer, partly because the people who receive it are a select group, typically younger and healthier than the broader Parkinson’s population.

A long-term follow-up study of 200 patients who had lived at least 10 years after deep brain stimulation surgery found a survival probability of 51%, with a mean age at death of 73 years.¹² A 25-year single-center experience with subthalamic deep brain stimulation reported a median survival of about 13 years after surgery.¹³ Those numbers are hard to compare directly with the broader Parkinson’s population because DBS candidates are usually in better overall health at the time of the procedure. Still, a mean death age of 73 for DBS patients compared with a general Parkinson’s population average near 78 does not suggest DBS extends life; if anything, it probably reflects that DBS recipients were diagnosed at younger ages and had more years of disease behind them by the time they died. The real value of DBS is in the quality of those years, not necessarily their number.

Racial and Geographic Disparities in Parkinson’s Mortality

Parkinson’s does not affect all populations equally, and neither does its mortality. A CDC-based analysis of U.S. death records spanning over two decades found that the white population had the highest age-adjusted mortality rate from Parkinson’s combined with dementia, at 11.16 per 100,000, followed by Hispanic or Latino individuals at 7.41, Black or African American individuals at 6.04, and Asian or Pacific Islander individuals at 5.53.¹⁴

Geography mattered too, with non-metropolitan areas showing a slightly higher mortality rate than metropolitan ones, and the Midwest region topping the four U.S. census regions.¹⁴ These disparities likely reflect a mix of factors: differences in environmental exposures (pesticide use in agricultural regions, for example), access to specialized neurological care, genetic predisposition patterns across ethnic groups, and possible underdiagnosis in communities with less access to healthcare. The lower recorded mortality in Black and Hispanic populations may partly reflect underdiagnosis rather than genuinely lower disease burden, which has been a persistent concern in Parkinson’s epidemiology.

The Diagnostic Accuracy Problem

Here is something that quietly undermines every survival statistic you read about Parkinson’s: the diagnosis itself is not as reliable as most people assume. A study tracking diagnostic stability over 10 years found that among the small fraction of deceased patients who received a postmortem brain examination (just 3%), only 64% had the initial Parkinson’s diagnosis confirmed by neuropathology.¹⁵ That means more than a third of the people who died with a clinical label of Parkinson’s may have had something else entirely.

This has real implications for how we interpret average survival data. If the “Parkinson’s” group in a study includes people who actually had progressive supranuclear palsy, multiple system atrophy, or Lewy body dementia, and those conditions often have different survival profiles, then the reported average age of death for “Parkinson’s” is a blend of several diseases. This is not just a theoretical concern. It likely explains some of the variation between studies and may be part of why mortality ratios range from about 1.8 to nearly 2.8 depending on the cohort.

Biological Aging as a Predictor

Your chronological age is one thing; how old your body actually acts is another, and the gap between the two appears to predict mortality in Parkinson’s patients. A study using UK Biobank data examined a measure called PhenoAge, which estimates biological age based on blood markers and organ function rather than years since birth. Parkinson’s patients whose biological age was 60 or older had significantly worse survival than those whose biological age was below 60. Faster-than-expected biological aging, measured as positive “age acceleration,” was independently linked to higher mortality even after adjusting for other factors.¹⁶

This line of research is still maturing, but the practical implication is that two people diagnosed with Parkinson’s at the same chronological age can have very different outlooks depending on their overall metabolic health. Managing blood sugar, inflammation, kidney function, and other markers of general health is not peripheral to Parkinson’s care. It is directly relevant to survival.

Exercise and Physical Activity

Exercise is one of the few interventions that has evidence for benefits across nearly every dimension of Parkinson’s disease, from motor symptoms and balance to mood and possibly even disease progression. A review of the accumulating evidence found that people with Parkinson’s benefit from physical activity in multiple ways, including general health improvements and potentially disease-modifying effects.¹⁷ A two-year follow-up study of exercisers with Parkinson’s found that participation in high-intensity exercise programs helped maintain health and functional ability over time.¹⁸

The evidence is not strong enough to say exercise adds a specific number of years to life, and it would be misleading to claim that. But maintaining physical function delays the cascade of complications, particularly falls, immobility, and aspiration, that are the actual proximate causes of death in late-stage disease. For someone newly diagnosed, starting or maintaining a vigorous exercise routine is one of the most concretely useful things they can do.

Palliative Care and the Final Stage

One of the least discussed aspects of Parkinson’s is how poorly the healthcare system handles its final years. Palliative care, which focuses on symptom relief and quality of life rather than cure, is widely recognized as relevant for advanced Parkinson’s, but in practice it is often introduced far too late or not at all. Persistent misconceptions, including the belief that palliative care is the same as giving up, contribute to delayed or absent referrals.¹⁹

An interdisciplinary clinic model that combined movement-disorder neurology with palliative care found that among 58 patients who died during the study period, 69% were enrolled in hospice at the time of death.²⁰ That figure sounds high, but it was the product of a deliberate, specialized program. In typical clinical settings, the rate of hospice enrollment for Parkinson’s patients at the end of life is far lower. The median time from symptom onset to the first visit at that specialized clinic was 7 years, meaning many patients were already deep into their disease course before receiving integrated palliative support.²⁰ For families navigating advanced Parkinson’s, asking a neurologist about palliative care early, well before the final months, can significantly improve comfort and reduce crisis-driven hospitalizations.

1
Journal of Movement Disorders. The Queensland Parkinson’s Project: An Overview of 20 Years of Mortality from Parkinson’s Disease
2
PubMed Central. Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study
3
PubMed Central. Mortality in Levodopa-Treated Parkinson’s Disease
4
PubMed Central. Increased Mortality in Young-Onset Parkinson’s Disease
5
PubMed Central. Mortality and causes of death in patients with Parkinson’s disease: a nationwide population-based cohort study
6
PubMed Central. Mortality rate, main causes of death and factors associated with higher mortality hazard in late stage Parkinson’s disease
7
Scientific Reports. Cardiovascular outcomes in Parkinson’s disease patients from a retrospective cohort study
8
PubMed Central. The APOE ε4 allele affects the survival of patients with Parkinson’s disease independent of dementia
9
PubMed Central. Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study
10
PubMed. Survival rates among Parkinson’s disease patients who carry mutations in the LRRK2 and GBA genes
11
MDS Abstracts. Survival of patients with Parkinson’s disease is influenced by the mutations in the LRRK2 but not GBA gene
12
PubMed. Long-term outcomes following deep brain stimulation for Parkinson’s disease
13
PubMed Central. Survival after Subthalamic Deep Brain Stimulation for Parkinson’s Disease: 25-Year Experience from a Single Center
14
PubMed Central. National Trends and Demographic Disparities in Mortality Involving Co-Recorded Parkinson’s Disease and Dementia in the United States, 1999–2025: A CDC WONDER Analysis
15
PubMed Central. Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years
16
PubMed Central. Biological aging predicts mortality in Parkinson’s patients: evidence from UK Biobank
17
PubMed Central. Role of Physical Activity in Parkinson’s Disease
18
PubMed. Predictors of outcomes in exercisers with Parkinson disease: A two-year longitudinal cohort study
19
PubMed Central. Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease
20
PubMed Central. The AIMS Clinic Model: A Retrospective Analysis of Interdisciplinary Movement-Neuropalliative Care for People With Late-Stage Parkinsonism